Prenatal diagnosis and successful intrauterine treatment of a female fetus with 21‐hydroxylase deficiency

Abstract

Role of transforming growth factor-alpha-related peptides in the autocrine/paracrine control of experimental breast cancer growth in vitro by estradiol, prolactin and progesterone.

Technical Report: Congenital Adrenal Hyperplasia

“…17,45,49,50 In a report of intrauterine growth retardation in an infant treated successfully for CAH, however, it was concluded that intrauterine growth retardation still should be considered "a possible fetal complication of treatment." 46 In long-term follow-up of most infants treated throughout the pregnancy or treated prenatally until midgestation, 17,44 -50 development seems to be normal, and growth has been consistent with the family pattern and that of the other affected siblings. 17,41,42,44,45 Rare adverse events, including failure to thrive and psychomotor and psychosocial delay in development, have been observed.…”

“…In some cases, treatment was interrupted for 5 to 7 days before amniocentesis, and, in a few cases, treatment was discontinued at 21 to 26 weeks. 18,[21][22][23][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53]…”

Prenatal Treatment of Congenital Adrenal Hyperplasia

“…However, several adverse events have been reported in children treated during foetal life. These include isolated cases of cardiac septal hypertrophy (22), hydrocephalus (15), hydrometrocolpos (20) and intrauterine growth retardation (19). The Swedish series included more adverse events than other published studies.…”